Case number 2018-1485
ARCH Development Corp. v. OSI Pharmaceuticals, LLC > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 23, 2021 | 0 | ARCH DEVELOPMENT CORP. v. OSI PHARMACEUTICALS, LLC [RULE 36 JUDGMENT] [nonprecedential] (0) |
| Jul 1, 2019 | 87 | Mandate issued to the United States Patent and Trademark Office. Service as of this date by the Clerk of Court. [618075] [JAB] [Entered: 07/01/2019 10:30 AM] (0) |
| May 9, 2019 | 86 | JUDGMENT filed. AFFIRMED. Issued pursuant to Federal Circuit Rule 36. Terminated on the merits after oral argument. COSTS: Costs taxed against Appellant(s). Mandate to issue in due course. For information regarding costs, petitions for rehearing, and petitions for writs of certiorari click here. [606092] [JAB] [Entered: 05/09/2019 09:37 AM] (0) |
| May 7, 2019 | 85 | Submitted after ORAL ARGUMENT by Mr. Peter A. Sullivan, Esq. for ARCH Development Corporation and Dana-Farber Cancer Institute, Inc., Brian Robert Matsui for Genentech, Inc. and OSI Pharma ceuticals, LLC and Katherine Twomey Allen for US. Panel: Judge: Prost , Judge: Lourie , Judge: Bryson. [605443] [JCP] [Entered: 05/07/2019 10:34 AM] (0) |
| Apr 19, 2019 | 84 | RESPONSE of Appellants ARCH Development Corporation and Dana-Farber Cancer Institute, Inc. to the supplemental authority [83] filed by Appellees Genentech, Inc. and OSI Pharmaceuticals, LLC. Service: 04/19/2019 by email, US mail. [601626] [18-1485] [Peter Sullivan] [Entered: 04/19/2019 12:29 PM] (0) |
| Apr 16, 2019 | 81 | Notice to counsel for Appellant Dana-Farber Cancer Institute, Inc.: The record of this case indicates that the Response to Notice of Oral Argument has not been filed. The response was due on or before 04/15/2019. Counsel must promptly docket the Response to Notice of Oral Argument event and designate which attorney will present argument for the party. Service as of this date by the Clerk of Court. [600473] [JAB] [Entered: 04/16/2019 09:40 AM] (0) |
| Apr 16, 2019 | 82 | AMENDED Response to notice of oral argument from the Appellants ARCH Development Corporation and Dana-Farber Cancer Institute, Inc.. [600747] [18-1485] [Peter Sullivan] [Entered: 04/16/2019 03:42 PM] (0) |
| Apr 16, 2019 | 83 | Citation of Supplemental Authority pursuant to Fed. R. App. P. 28(j) for Appellees Genentech, Inc. and OSI Pharmaceuticals, LLC. Service: 04/16/2019 by email, US mail. [600822] [18-1485] [Brian Matsui] [Entered: 04/16/2019 05:44 PM] (0) |
| Apr 15, 2019 | 80 | Response to notice of oral argument from the Appellees Genentech, Inc. and OSI Pharmaceuticals, LLC. [599940] [18-1485] [Brian Matsui] [Entered: 04/15/2019 09:53 AM] (0) |
| Apr 12, 2019 | 79 | Response to notice of oral argument from the Intervenor US. [599846] [18-1485] [Katherine Allen] [Entered: 04/12/2019 08:59 PM] (0) |
| Apr 8, 2019 | 78 | Response to notice of oral argument from the Appellant ARCH Development Corporation. [598494] [18-1485] [Peter Sullivan] [Entered: 04/08/2019 03:28 PM] (0) |
| Mar 21, 2019 | 77 | NOTICE OF ORAL ARGUMENT. Panel: 1905F. Case scheduled May 07, 2019 10:00 a.m. at the United States Court of Appeals for the Federal Circuit (Howard T. Markey National Courts Building, 717 Madison Place, NW Washington, DC 20439), Courtroom 203. Response to Notice of Oral Argument due: 04/15/2019. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. [594705] [JAB] [Entered: 03/21/2019 04:13 PM] (2) |
| Mar 1, 2019 | 76 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re:attorney entry of appearance Docket No. [75], ERROR: The contact information listed on the entry of appearance for Stephen Kenny does not match the information in the attorney's user account. CORRECTION: Please update as needed to ensure the contact information on the entry of appearance and in the user account matches. [589846] [MMA] [Entered: 03/01/2019 05:18 PM] (0) |
| Feb 28, 2019 | 75 | Amended Entry of appearance for Stephen Kenny as of counsel for Appellants ARCH Development Corporation and Dana-Farber Cancer Institute, Inc.. Service: 02/28/2019 by email, US mail. [589465] [18-1485] [Peter Sullivan] [Entered: 02/28/2019 02:45 PM] (2) |
| Feb 28, 2019 | 74 | Amended Entry of appearance for Peter A. Sullivan as principal counsel for Appellants ARCH Development Corporation and Dana-Farber Cancer Institute, Inc.. Service: 02/28/2019 by email, US mail. [589463] [18-1485] [Peter Sullivan] [Entered: 02/28/2019 02:37 PM] (2) |
| Jan 16, 2019 | 73 | Notice of Appointment of New Solicitor for the U.S. Patent and Trademark Office. Service: 01/22/2019 by clerk. [579573] [17-2257, 17-2304, 17-2323, 17-2593, 17-2621, 18-1047, 18-1048, 18-1070, 18-1105, 18-1163, 18-1302, 18-1311, 18-1368, 18-1385, 18-1438, 18-1443, 18-1485, 18-1489, 18-1659, 18-1768, 18-1772, 18-1876, 18-1883, 18-1901, 18-1925, 18-1933, 18-1944, 18-1968, 18-2000, 18-2031, 18-2032, 18-2069, 18-2082, 18-2106, 18-2170, 18-2236, 18-2271, 18-2329, 19-1049, 19-1117, 19-1334] [MJL] [Entered: 01/22/2019 10:12 AM] (1) |
| Nov 21, 2018 | 72 | Notice from Intervenor US regarding conflicts with oral argument. Service: 11/21/2018 by email, US mail. [567204] [18-1485] [Katherine Allen] [Entered: 11/21/2018 03:11 PM] (2) |
| Nov 21, 2018 | 71 | Notice from Appellants ARCH Development Corporation and Dana-Farber Cancer Institute, Inc. regarding conflicts with oral argument. Service: 11/21/2018 by email. [567093] [18-1485] [Peter Sullivan] [Entered: 11/21/2018 11:11 AM] (2) |
| Nov 21, 2018 | 70 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re:party letter Docket No. [67], ERROR: Counsel did not use the "Response to Notice to Advise of Scheduling Conflicts" form. CORRECTION: When filing future argument scheduling conflicts, counsel must complete and upload the Response to Notice to Advise of Scheduling Conflicts form. [567076] [JAB] [Entered: 11/21/2018 10:42 AM] (0) |
| Nov 21, 2018 | 69 | Notice from Appellee Genentech, Inc. regarding conflicts with oral argument. Service: 11/21/2018 by email, US mail. [567068] [18-1485] [Brian Matsui] [Entered: 11/21/2018 10:32 AM] (2) |
| Nov 21, 2018 | 68 | Notice from Appellee OSI Pharmaceuticals, LLC regarding conflicts with oral argument. None. Service: 11/21/2018 by email. [567053] [18-1485] [Thomas Saunders] [Entered: 11/21/2018 10:07 AM] (0) |
| Nov 21, 2018 | 67 | Notice from Appellants Dana-Farber Cancer Institute, Inc. and ARCH Development Corporation regarding conflicts with oral argument. Service: 11/21/2018 by email. [567043] [18-1485] [Peter Sullivan] [Entered: 11/21/2018 09:43 AM] (2) |
| Nov 16, 2018 | 66 | 6 paper copies of the Joint Appendix Brief (Vol. I - II) [64] received from Appellants ARCH Development Corporation and Dana-Farber Cancer Institute, Inc.. [565908] [CJF] [Entered: 11/16/2018 03:26 PM] (0) |
| Nov 14, 2018 | 65 | Notice to Advise of Scheduling Conflicts. Please advise of any scheduling conflicts during the upcoming court session months listed in the attached Notice. The notice of conflict with oral argument is due on or before 11/21/2018. The Response to Notice to Advise of Scheduling Conflicts can be found here. The Oral Argument Guide can be found here. [565004] [MJL] [Entered: 11/14/2018 05:58 PM] (1) |
| Nov 7, 2018 | 63 | 6 paper copies of the Reply Brief [61] received from Appellants ARCH Development Corporation and Dana-Farber Cancer Institute, Inc.. [563267] [CJF] [Entered: 11/07/2018 01:41 PM] (0) |
| Nov 6, 2018 | 62 | TENDERED from Appellants ARCH Development Corporation and Dana-Farber Cancer Institute, Inc.. Title: JOINT APPENDIX. Service: 11/06/2018 by email, US mail. [562956] [18-1485] [Peter Sullivan] [Entered: 11/06/2018 01:54 PM] (774) |
| Nov 6, 2018 | 64 | APPENDIX FILED for ARCH Development Corporation and Dana-Farber Cancer Institute, Inc. [62]. Number of Pages: 774. Service: 11/06/2018 by email. The paper copies of the appendix should be received by the court on or before 11/21/2018. [565000] [MJL] [Entered: 11/14/2018 05:51 PM] (774) |
| Oct 30, 2018 | 61 | REPLY BRIEF FILED for Appellants ARCH Development Corporation and Dana-Farber Cancer Institute, Inc. [60]. Number of Pages: 30. Service: 10/30/2018 by email. The paper copies of the brief should be received by the court on or before 11/13/2018. Appendix is due 11/06/2018. [562642] [MJL] [Entered: 11/05/2018 02:25 PM] (38) |
| Oct 30, 2018 | 60 | TENDERED from Appellants ARCH Development Corporation and Dana-Farber Cancer Institute, Inc.. Title: REPLY BRIEF. Service: 10/30/2018 by email, US mail. [561457] [18-1485] [Peter Sullivan] [Entered: 10/30/2018 04:37 PM] (38) |
| Oct 24, 2018 | 59 | 6 paper copies of the Opening Response Brief [57] received from Appellees Genentech, Inc. and OSI Pharmaceuticals, LLC. [560131] [CJF] [Entered: 10/24/2018 04:28 PM] (0) |
| Oct 23, 2018 | 58 | 6 paper copies of the Intervenor Brief [56] received from Intervenor US. [559721] [CJF] [Entered: 10/23/2018 04:27 PM] (0) |
| Oct 16, 2018 | 57 | BRIEF FILED for Appellees Genentech, Inc. and OSI Pharmaceuticals, LLC [55]. Number of Pages: 55. Service: 10/16/2018 by email. The paper copies of the brief should be received by the court on or before 10/30/2018. Appellants' reply brief is due 10/30/2018. [559509] [MJL] [Entered: 10/23/2018 12:27 PM] (67) |
| Oct 16, 2018 | 56 | BRIEF FILED for Intervenor US [54]. Number of Pages: 41. Service: 10/16/2018 by email. The paper copies of the brief should be received by the court on or before 10/30/2018. [559508] [MJL] [Entered: 10/23/2018 12:21 PM] (51) |
| Oct 16, 2018 | 55 | TENDERED from Appellees Genentech, Inc. and OSI Pharmaceuticals, LLC. Title: RESPONSE BRIEF. Service: 10/16/2018 by email. [557808] [18-1485] [Brian Matsui] [Entered: 10/16/2018 04:21 PM] (67) |
| Oct 16, 2018 | 54 | TENDERED from Intervenor US. Title: INTERVENOR BRIEF. Service: 10/16/2018 by email. [557789] [18-1485] [Katherine Allen] [Entered: 10/16/2018 03:49 PM] (51) |
| Sep 12, 2018 | 53 | Entry of appearance for Joseph Matal as of counsel for Intervenor US. Service: 09/12/2018 by email. [549078] [18-1485] [Joseph Matal] [Entered: 09/12/2018 09:57 AM] (2) |
| Sep 12, 2018 | 52 | Entry of appearance for Thomas W. Krause as of counsel for Intervenor US. Service: 09/12/2018 by email. [549073] [18-1485] [Thomas Krause] [Entered: 09/12/2018 09:50 AM] (2) |
| Sep 12, 2018 | 51 | Entry of appearance for Farheena Y. Rasheed as of counsel for Intervenor US. Service: 09/12/2018 by email. [549066] [18-1485] [Farheena Rasheed] [Entered: 09/12/2018 09:35 AM] (2) |
| Sep 6, 2018 | 50 | ORDER filed. The motion [49] is granted. The revised official caption is reflected in the order. The stay is lifted. The response briefs of the appellees and the United States are due no later than 40 days from the date of filing of this order. Service: 09/06/2018 by clerk. [547645] [LMS] [Entered: 09/06/2018 12:00 PM] (2) |
| Aug 30, 2018 | 49 | MOTION of United States for leave to intervene [Consent: unopposed]. Service: 08/30/2018 by email. [546557] [18-1485] [Katherine Allen] [Entered: 08/30/2018 05:54 PM] (4) |
| Aug 30, 2018 | 48 | Entry of appearance for Scott R. McIntosh as of counsel for United States (intervenor). Service: 08/30/2018 by email. [546492] [18-1485] [Scott McIntosh] [Entered: 08/30/2018 03:03 PM] (1) |
| Aug 30, 2018 | 47 | Entry of appearance for Katherine Twomey Allen as principal counsel for United States. Service: 08/30/2018 by email. [546471] [18-1485] [Katherine Allen] [Entered: 08/30/2018 02:38 PM] (2) |
| Jul 31, 2018 | 46 | ORDER filed. Notice of the appellant's constitutional challenge [39] is hereby certified to the Attorney General. No later than 30 days from the date of filing of this order, the Attorney General is directed to inform this court whether the United States intends to intervene in this appeal. The proceedings in the above-captioned appeal are stayed. Service: 07/31/2018 by clerk. [539858] [LMS] [Entered: 07/31/2018 04:05 PM] (2) |
| Jul 24, 2018 | 45 | 6 paper copies of the Corrected Opening Brief [44] received from Appellants ARCH Development Corporation and Dana-Farber Cancer Institute, Inc.. [538211] [CJF] [Entered: 07/24/2018 02:42 PM] (0) |
| Jul 17, 2018 | 43 | Notice of Correction to the Brief Doc No. [42] for Appellants ARCH Development Corporation and Dana-Farber Cancer Institute, Inc.. Service: 07/17/2018 by email. [536650] [18-1485] [Peter Sullivan] [Entered: 07/17/2018 04:39 PM] (2) |
| Jul 17, 2018 | 44 | CORRECTED BRIEF FILED for Appellants ARCH Development Corporation and Dana-Farber Cancer Institute, Inc. [42]. Number of Pages: 49. Service: 07/17/2018 by email. The paper copies of the brief should be received by the court on or before 07/27/2018. [537430] [MJL] [Entered: 07/20/2018 03:52 PM] (189) |
| Jul 17, 2018 | 42 | TENDERED from Appellants ARCH Development Corporation and Dana-Farber Cancer Institute, Inc.. Title: CORRECTED OPENING BRIEF. Service: 07/17/2018 by email. [536647] [18-1485] [Peter Sullivan] [Entered: 07/17/2018 04:37 PM] (189) |
| Jul 10, 2018 | 41 | TENDERED from Appellants ARCH Development Corporation and Dana-Farber Cancer Institute, Inc.. Title: CORRECTED OPENING BRIEF. Service: 07/10/2018 by email. [534749] [18-1485]. This brief has been corrected. See Doc. No. [44]. [Peter Sullivan] [Entered: 07/10/2018 11:08 AM] (0) |
| Jul 10, 2018 | 40 | Notice of Correction to the Brief Doc No. [36] for Appellants ARCH Development Corporation and Dana-Farber Cancer Institute, Inc.. Service: 07/10/2018 by email. [534748] [18-1485] [Peter Sullivan] [Entered: 07/10/2018 11:05 AM] (3) |
| Jul 9, 2018 | 38 | ORDER filed. The stay of the briefing schedule is lifted. Appeal No. 2018-1549 is dismissed. Each side shall bear its own costs in Appeal No. 2018-1549. OSI's brief, not to exceed 14,000 words, is due within 40 days of the date of this order. The revised official caption is reflected in the order. Service: 07/09/2018 by clerk. [534302] [18-1485, 18-1549] [LMS] [Entered: 07/09/2018 10:37 AM] (3) |
| Jul 9, 2018 | 39 | Notice from Appellants ARCH Development Corporation and Dana-Farber Cancer Institute, Inc. Rule 44 (a) Notice of Constitutional Challenge. Service: 07/09/2018 by email. [534581] [18-1485] [Peter Sullivan] [Entered: 07/09/2018 04:50 PM] (3) |
| May 21, 2018 | 36 | TENDERED from Appellants ARCH Development Corporation and Dana-Farber Cancer Institute, Inc.. Title: OPENING BRIEF. Service: 05/21/2018 by email. [523196] [18-1485]. This brief has been corrected. See Doc. No. [44]. [Peter Sullivan] [Entered: 05/21/2018 01:00 PM] (0) |
| May 21, 2018 | 37 | The brief submitted by Appellants ARCH Development Corporation and Dana-Farber Cancer Institute, Inc. [36] cannot be filed at this time; reason: Order staying appeal filed 2/28. [524062] [CFT] [Entered: 05/23/2018 04:31 PM] (0) |
| May 7, 2018 | 35 | Citation of Supplemental Authority pursuant to Fed. R. App. P. 28(j) for Cross-Appellants Genentech, Inc. and OSI Pharmaceuticals, LLC. Service: 05/07/2018 by email. [519761] [18-1485] [Brian Matsui] [Entered: 05/07/2018 04:22 PM] (25) |
| Mar 21, 2018 | 34 | Certified list from the United States Patent and Trademark Office. Service: 03/21/2018 by email. [507050] [18-1485, 18-1549] [MJL] [Entered: 03/22/2018 09:51 AM] (110) |
| Mar 13, 2018 | 33 | RESPONSE of Cross-Appellants Genentech, Inc. and OSI Pharmaceuticals, LLC to the court order to show cause [32] ,court order [32]. Service: 03/13/2018 by email. [504470] [Thomas Saunders] [Entered: 03/13/2018 09:20 AM] (8) |
| Feb 28, 2018 | 32 | ORDER filed. OSI and Genentech are directed to show cause within 14 days of the date of this order as to why Appeal No. 2018-1549 should not be dismissed and why the revised caption for Appeal No. 18-1485 should not indicate that they are appellees. The briefing schedule is stayed. Service: 02/28/2018 by clerk. [501699] [LMS] [Entered: 02/28/2018 11:38 AM] (2) |
| Feb 14, 2018 | 31 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: ERROR: DeAnn Smith (Entry of Appearance [29]) is not a registered filer with CM/ECF for the Federal Circuit. CORRECTION: Pursuant to FCR 25(a)(2), attorneys who appear before this court must register for the court's CM/ECF system. Please register promptly. [497573] [MJL] [Entered: 02/14/2018 10:47 AM] (0) |
| Feb 13, 2018 | 23 | NOTICE OF DEFICIENCY: The entries of appearance for Peter A. Sullivan [13], DeAnn Smith [14], and Stephen Kenny [15] filed by Appellants ARCH Development Corporation and Dana-Farber Cancer Institute, Inc. in 18-1485 are without proof of service and therefore cannot be accepted for filing at this time. You are being afforded the opportunity to correct the deficiency. At the discretion of the court, the corrected documents may be accepted for filing if received before midnight (EST) on the date of this notice. [497327] [MJL] [Entered: 02/13/2018 11:43 AM] (0) |
| Feb 13, 2018 | 30 | Corrected Entry of appearance for Stephen Kenny as of counsel for Appellants ARCH Development Corporation and Dana-Farber Cancer Institute, Inc.. Service: 02/13/2018 by email. [497472] [Peter Sullivan] [Entered: 02/13/2018 04:52 PM] (2) |
| Feb 13, 2018 | 29 | Corrected Entry of appearance for DeAnn Smith as of counsel for Appellants ARCH Development Corporation and Dana-Farber Cancer Institute, Inc.. Service: 02/13/2018 by email. [497469] [Peter Sullivan] [Entered: 02/13/2018 04:49 PM] (2) |
| Feb 13, 2018 | 28 | Corrected Entry of appearance for Peter A. Sullivan as principal counsel for Appellants ARCH Development Corporation and Dana-Farber Cancer Institute, Inc.. Service: 02/13/2018 by email. [497465] [Peter Sullivan] [Entered: 02/13/2018 04:45 PM] (2) |
| Feb 13, 2018 | 27 | Corrected Certificate of Interest for the Appellants ARCH Development Corporation and Dana-Farber Cancer Institute, Inc.. Service: 02/13/2018 by email. [497460] [Peter Sullivan] [Entered: 02/13/2018 04:40 PM] (3) |
| Feb 13, 2018 | 26 | Corrected Docketing Statement for the Appellants ARCH Development Corporation and Dana-Farber Cancer Institute, Inc.. Service: 02/13/2018 by email. [497457] [Peter Sullivan] [Entered: 02/13/2018 04:38 PM] (4) |
| Feb 13, 2018 | 25 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: ERROR: Appellants' docketing statement [11] was not fully text-searchable. CORRECTION: Pursuant to FCR 25(c)(1)(K) and 25(d), documents must be text-searchable. Please ensure future filings are text-searchable in their entirety. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [497330] [MJL] [Entered: 02/13/2018 11:47 AM] (0) |
| Feb 13, 2018 | 24 | NOTICE OF DEFICIENCY: The certificate of interest [12] filed by Appellants ARCH Development Corporation and Dana-Farber Cancer Institute, Inc. in 18-1485 is incomplete and without proof of service and therefore cannot be accepted for filing at this time. Item #2 was left blank. You are being afforded the opportunity to correct the deficiencies. All items must be filled out for all represented parties. At the discretion of the court, the corrected document may be accepted for filing if received before midnight (EST) on the date of this notice. [497329] [MJL] [Entered: 02/13/2018 11:45 AM] (0) |
| Feb 12, 2018 | 18 | Docketing Statement for the Cross-Appellant Genentech, Inc.. Service: 02/12/2018 by email. [497162] [Brian Matsui] [Entered: 02/12/2018 05:46 PM] (4) |
| Feb 12, 2018 | 22 | Docketing Statement for the Cross-Appellant OSI Pharmaceuticals, LLC. Service: 02/12/2018 by email. [497170] [Thomas Saunders] [Entered: 02/12/2018 06:07 PM] (4) |
| Feb 12, 2018 | 21 | Entry of appearance for Matthew A. Chivvis as of counsel for Cross-Appellant Genentech, Inc.. Service: 02/12/2018 by email. [497167] [Matthew Chivvis] [Entered: 02/12/2018 05:56 PM] (2) |
| Feb 12, 2018 | 20 | Entry of appearance for Matthew I. Kreeger as of counsel for Cross-Appellant Genentech, Inc.. Service: 02/12/2018 by email. [497165] [Matthew Kreeger] [Entered: 02/12/2018 05:53 PM] (2) |
| Feb 12, 2018 | 19 | Entry of appearance for Seth W. Lloyd as of counsel for Cross-Appellant Genentech, Inc.. Service: 02/12/2018 by email. [497163] [Seth Lloyd] [Entered: 02/12/2018 05:51 PM] (2) |
| Feb 12, 2018 | 3 | Entry of appearance for Thomas G. Saunders as principal counsel for Cross-Appellant OSI Pharmaceuticals, LLC. Service: 02/12/2018 by email. [497051] [Thomas Saunders] [Entered: 02/12/2018 01:35 PM] (2) |
| Feb 12, 2018 | 17 | Certificate of Interest for the Cross-Appellant Genentech, Inc.. Service: 02/12/2018 by email. [497161] [Brian Matsui] [Entered: 02/12/2018 05:46 PM] (2) |
| Feb 12, 2018 | 16 | Entry of appearance for Brian R. Matsui as principal counsel for Cross-Appellant Genentech, Inc.. Service: 02/12/2018 by email. [497160] [Brian Matsui] [Entered: 02/12/2018 05:45 PM] (2) |
| Feb 12, 2018 | 15 | Entry of appearance for Stephen Kenny as of counsel for Appellants ARCH Development Corporation and Dana-Farber Cancer Institute, Inc.. Service: 02/12/2018 by email. [497144] [Peter Sullivan] [Entered: 02/12/2018 04:24 PM] (0) |
| Feb 12, 2018 | 14 | Entry of appearance for DeAnn Smith as of counsel for Appellants ARCH Development Corporation and Dana-Farber Cancer Institute, Inc.. Service: 02/12/2018 by email. [497143] [Peter Sullivan] [Entered: 02/12/2018 04:22 PM] (0) |
| Feb 12, 2018 | 13 | Entry of appearance for Peter A. Sullivan as principal counsel for Appellants ARCH Development Corporation and Dana-Farber Cancer Institute, Inc.. Service: 02/12/2018 by email. [497142] [Peter Sullivan] [Entered: 02/12/2018 04:20 PM] (0) |
| Feb 12, 2018 | 12 | Certificate of Interest for the Appellants ARCH Development Corporation and Dana-Farber Cancer Institute, Inc.. Service: 02/12/2018 by email. [497138] [Peter Sullivan] [Entered: 02/12/2018 04:13 PM] (0) |
| Feb 12, 2018 | 11 | Docketing Statement for the Appellants ARCH Development Corporation and Dana-Farber Cancer Institute, Inc.. Service: 02/12/2018 by email. [497129] [Peter Sullivan] [Entered: 02/12/2018 04:07 PM] (3) |
| Feb 12, 2018 | 10 | Certificate of Interest for the Cross-Appellant OSI Pharmaceuticals, LLC. Service: 02/12/2018 by email. [497061] [Thomas Saunders] [Entered: 02/12/2018 01:47 PM] (3) |
| Feb 12, 2018 | 9 | Entry of appearance for Timothy A. Cook as of counsel for Cross-Appellant OSI Pharmaceuticals, LLC. Service: 02/12/2018 by email. [497059] [Timothy Cook] [Entered: 02/12/2018 01:46 PM] (2) |
| Feb 12, 2018 | 8 | Entry of appearance for Heather M. Petruzzi as of counsel for Cross-Appellant OSI Pharmaceuticals, LLC. Service: 02/12/2018 by email. [497058] [Heather Petruzzi] [Entered: 02/12/2018 01:44 PM] (2) |
| Feb 12, 2018 | 7 | Entry of appearance for Amanda L. Major as of counsel for Cross-Appellant OSI Pharmaceuticals, LLC. Service: 02/12/2018 by email. [497057] [Amanda Major] [Entered: 02/12/2018 01:43 PM] (2) |
| Feb 12, 2018 | 6 | Entry of appearance for Emily R. Whelan as of counsel for Cross-Appellant OSI Pharmaceuticals, LLC. Service: 02/12/2018 by email. [497055] [Emily Whelan] [Entered: 02/12/2018 01:41 PM] (2) |
| Feb 12, 2018 | 5 | Entry of appearance for David L. Cavanaugh as of counsel for Cross-Appellant OSI Pharmaceuticals, LLC. Service: 02/12/2018 by email. [497053] [David Cavanaugh] [Entered: 02/12/2018 01:40 PM] (2) |
| Feb 12, 2018 | 4 | Entry of appearance for Amy K. Wigmore as of counsel for Cross-Appellant OSI Pharmaceuticals, LLC. Service: 02/12/2018 by email. [497052] [Amy Wigmore] [Entered: 02/12/2018 01:38 PM] (2) |
| Feb 9, 2018 | 2 | Note to file: The following cases are consolidated: 18-1485 (Lead) with 18-1549 (Cross-Appeal). FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [496813] [18-1485, 18-1549] [MJL] [Entered: 02/09/2018 04:20 PM] (0) |
| Jan 29, 2018 | 1 | Appeal docketed. Received: 01/26/2018. [493249] Entry of Appearance due 02/12/2018. Certificate of Interest due 02/12/2018. Docketing Statement due 02/12/2018. Certified List due 03/12/2018. [MJL] [Entered: 01/29/2018 10:13 AM] (59) |
